Aimee Mishkin
Vice President, Head of Regulatory Affairs at Kymera Therapeutics - Watertown Town, MA, US
Aimee Mishkin's Colleagues at Kymera Therapeutics
Aimee Mishkin's Contact Details
857-285-5300
United States
Kymera Therapeutics
Aimee Mishkin's Company Details
Kymera is a clinical stage biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. Kymera's proprietary targeted protein degradation platform, called Pegasus, enables us to discover highly selective small molecule protein degraders with activity against disease-causing proteins throughout the body. We believe that our small molecule protein degraders have significant advantages over existing therapies and allow us to address a large portion of the human genome that was previously intractable with traditional modalities. Kymera focuses on biological pathways that have been clinically validated but where key biological nodes/proteins have not been drugged or have been inadequately drugged. To date, we have utilized our Pegasus platform to design novel protein degraders focused in the areas of immunology-inflammation and oncology, and continue to apply our platform's capabilities to additional therapeutic areas. Learn more at www.kymeratx.com